AR029619A1 - VACCINE - Google Patents

VACCINE

Info

Publication number
AR029619A1
AR029619A1 ARP000100821A ARP000100821A AR029619A1 AR 029619 A1 AR029619 A1 AR 029619A1 AR P000100821 A ARP000100821 A AR P000100821A AR P000100821 A ARP000100821 A AR P000100821A AR 029619 A1 AR029619 A1 AR 029619A1
Authority
AR
Argentina
Prior art keywords
medicine
refers
ige
new
regions
Prior art date
Application number
ARP000100821A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Smithkline Beecham Biolog, Peptide Therapeutics Ltd filed Critical Smithkline Beecham Biolog
Publication of AR029619A1 publication Critical patent/AR029619A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a proporcionar nuevos medicamentos para el tratamiento, prevencion o alivio de enfermedades alérgicas. En particular, los nuevos medicamentos son epítopos o mimotopos derivados de los dominios Ce3 y Ce4 de IgE. Estas nuevas regiones pueden ser la diana de inmunoprofilaxis o inmunoterapia activa o pasiva. La presente se refiere además a procedimientos para producir los medicamentos, a composiciones farmacéuticas que contienen los mismos y a su uso en medicina. También constituyen un aspecto de la presente ligandos, en especial anticuerpos monoclonales, que pueden unirse a las regiones de IgE de la invencion, y su uso en medicina como inmunoterapia pasiva.This refers to providing new medications for the treatment, prevention or relief of allergic diseases. In particular, the new drugs are epitopes or mimotopes derived from the Ce3 and Ce4 domains of IgE. These new regions may be the target of immunoprophylaxis or active or passive immunotherapy. This also refers to procedures for producing the medicines, pharmaceutical compositions containing them and their use in medicine. They also constitute an aspect of the present ligands, especially monoclonal antibodies, which can bind to the IgE regions of the invention, and their use in medicine as passive immunotherapy.

ARP000100821A 1999-02-25 2000-02-25 VACCINE AR029619A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine

Publications (1)

Publication Number Publication Date
AR029619A1 true AR029619A1 (en) 2003-07-10

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100821A AR029619A1 (en) 1999-02-25 2000-02-25 VACCINE

Country Status (18)

Country Link
EP (1) EP1155038A1 (en)
JP (1) JP2002537403A (en)
KR (1) KR20020007314A (en)
CN (1) CN1520423A (en)
AR (1) AR029619A1 (en)
AU (1) AU3281100A (en)
CA (1) CA2363641A1 (en)
CO (1) CO5231139A1 (en)
CZ (1) CZ20013081A3 (en)
HK (1) HK1043134A1 (en)
HU (1) HUP0105490A3 (en)
IL (1) IL145025A0 (en)
MX (1) MXPA01008612A (en)
NO (1) NO20014131L (en)
NZ (1) NZ513680A (en)
PL (1) PL350992A1 (en)
TR (1) TR200102493T2 (en)
WO (1) WO2000050461A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045745A2 (en) * 1999-12-21 2001-06-28 Acambis Research Limited A reversible linkage technology for controlled conjugation
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
JP2003047482A (en) 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
DE60234375D1 (en) 2001-09-14 2009-12-24 Cytos Biotechnology Ag PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
EP1532167B1 (en) 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
KR101228376B1 (en) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 Hapten-carrier conjugates and uses thereof
RU2450827C2 (en) 2002-07-19 2012-05-20 Цитос Биотехнологи Аг Vaccine compositions containing beta 1-6 amyloid antigen array
RU2351362C2 (en) 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг CONJUGATES OF PEPTIDE Melan-A, VIRUS-LIKE PARTICLE ANALOGUE
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
SG149892A1 (en) * 2004-02-02 2009-02-27 Tanox Inc Identification of novel ige epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2624081C (en) 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007144150A1 (en) 2006-06-12 2007-12-21 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
CN102245198B (en) 2008-12-09 2016-08-17 辉瑞疫苗有限责任公司 IgE CH3 peptide vaccine
EP2942061A3 (en) * 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2862873B1 (en) * 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. IgE PEPTIDE VACCINE
CA3096363C (en) * 2018-04-06 2024-04-16 Slsbio Co., Ltd. Novel epitope of immunoglobulin e, antibody binding thereto, and kit for analyzing immunoglobulin e in sample containing same
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (en) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd Peptide having anti-allergic activity
ES2193136T3 (en) * 1991-08-14 2003-11-01 Genentech Inc IMMUNOGLUBINE VARIANTS FOR SPECIFIC RECEIVERS OF FC EPSILON.
IL125590A (en) * 1996-03-01 2001-08-26 Novartis Ag Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
MXPA01008612A (en) 2003-06-24
EP1155038A1 (en) 2001-11-21
NZ513680A (en) 2001-09-28
IL145025A0 (en) 2002-06-30
HUP0105490A3 (en) 2002-05-28
WO2000050461A1 (en) 2000-08-31
PL350992A1 (en) 2003-02-24
HUP0105490A2 (en) 2002-04-29
AU3281100A (en) 2000-09-14
TR200102493T2 (en) 2002-02-21
CO5231139A1 (en) 2002-12-27
HK1043134A1 (en) 2002-09-06
KR20020007314A (en) 2002-01-26
NO20014131D0 (en) 2001-08-24
CA2363641A1 (en) 2000-08-31
CZ20013081A3 (en) 2002-02-13
CN1520423A (en) 2004-08-11
JP2002537403A (en) 2002-11-05
NO20014131L (en) 2001-10-02

Similar Documents

Publication Publication Date Title
AR029619A1 (en) VACCINE
EA201992590A1 (en) STABLE COMPOSITIONS OF ANTIBODIES TO THE RECIPE OF PROGRAMMABLE DAMAGE 1 (PD-1) AND WAYS OF THEIR APPLICATION
Harrison et al. Research strategies to improve snakebite treatment: Challenges and progress
MA47313A (en) SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES
AR066987A1 (en) MONOCLONAL ANTIBODY AGAINST BETA-AMYLIDE PROTEIN
EA201991763A1 (en) CCR7 ANTIBODY AND MEDICINE CONJUGATES
BR9607171A (en) Monoclonal anti-cd6 antibodies and their uses
CR10244A (en) TUMOR THERAPY WITH AN ANTIBODY AGAINST THE VASCULAR ENDOTELIAL GROWTH FACTOR AND AN ANTIBODY AGAINST THE HUMAN TYPE 2 EPITELIAL GROWTH FACTOR RECEIVER
ATE414534T1 (en) IMMUNOTHERAPEUTIC METHODS AND SYSTEMS
CR8698A (en) MONOCLONAL ANTIBODIES TO THE HEPATOCITE GROWTH FACTOR
EA200101064A1 (en) TREATMENT OF CANCER DISEASES THROUGH COMBINED INTRODUCTION OF A DOCETIXEL WITH RECOMBINANT HUMANIZED MONOCLONAL ANTI-HER2 ANTI-TITLES
AR069290A1 (en) MONOCLONAL ANTIBODIES THAT JOIN THE HGM -CSF (STIMULATING FACTOR OF THE COLONY OF GRANULOCITOS-MACROFAGOS) AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM
DK1684869T3 (en) Method of Therapy for B-Cell-Related Cancer Diseases
ES2376564B1 (en) USE OF ANTIBODIES AGAINST NK1, NK2 AND / OR NK3 RECEPTORS, TO PRODUCE APOPTOSIS IN TUMOR CELLS AND TO MODIFY STRAMA, IMMUNITY AND INTRA AND PERITUMORAL VASCULARIZATION, AS TREATMENT OF CANCER.
Sibaud et al. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series
AR045765A1 (en) MOLECULES OF UNION TO CD45 AND THERAPEUTIC USE
CL2022003715A1 (en) Tubulysins and protein-tubulysin conjugates
EA201500506A1 (en) Conjugates and small molecules interacting with the CD16a receptor
RU2011130522A (en) MONOCLONAL ANTIBODY AGAINST HCV AS A MEDICINE FOR THE THERAPEUTIC TREATMENT AND PREVENTION OF HCV INFECTIONS
MX2021010766A (en) Tsg-6 antibodies and uses therefor.
Lee et al. Bee venom-associated Th1/Th2 immunoglobulin class switching results in immune tolerance of NZB/W F1 murine lupus nephritis
AR029336A1 (en) USEFUL PEPTIDES TO PREPARE MEDICINES FOR THE TREATMENT, PREVENTION OR IMPROVEMENT OF ALLERGIC STATES, IMMUNOGENS, EPITHOPES AND MIMOTOPES, VACCINES, LIGENDS, PHARMACEUTICAL COMPOSITIONS; USE OF THE PEPTIDES, OF THE LIGANDS IN THE PREPARATION OF MEDICINES; PROCESS TO PREPARE VACCINES AND PR
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
BR112023000455A2 (en) TREATMENT OF INFLAMMATORY DISEASE USING ANTI-TISSUE FACTOR ANTIBODIES
RU2015147913A (en) ANTIBODY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR

Legal Events

Date Code Title Description
FA Abandonment or withdrawal